Tegavivint
- Generic Name
- Tegavivint
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O6S2
- CAS Number
- 1227637-23-1
- Unique Ingredient Identifier
- 18AP231HUP
- Associated Conditions
- -
- Associated Therapies
- -
Tegavivint for Treating Patients with Relapsed or Refractory Large B-Cell Lymphoma
Phase 1
Recruiting
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsRefractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRefractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRefractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: Tegavivint
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Lapo Alinari
- Target Recruit Count
- 20
- Registration Number
- NCT05755087
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC V8Stage IVA Lung Cancer AJCC V8Stage IVB Lung Cancer AJCC V8
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-01-01
- Target Recruit Count
- 24
- Registration Number
- NCT04780568
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath